- (PLX AI) – Bayer says 2 large Xarelto studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease.
- • Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD)
- • The XATOA registry provides additional evidence of the benefit of a dual pathway inhibition (DPI) for patients with vascular disease at high risk of cardiovascular (CV) events in routine clinical practice
- • The studies reinforce the findings of the COMPASS study and provide additional confidence in DPI treatment in patients with CAD and/or PAD
Quelle: PLX AI